McCune-Albright Syndrome and acromegaly: Hormonal control with use of cabergoline and long-acting somatostatin - case report;Síndrome de McCune-albright associada à acromegalia: Controle hormonal com cabergolina e somatostatina de longa duração - relato de caso

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 53, Issue 1, 2009, Pages 102-106

  Almeida, João Paulo C ^a,b   Albuquerque, Lucas Alverne F ^a,b   Ferraz, Camila L H ^a   Mota, Ítalo ^a   Gondim, Jackson ^a   Ferraz, Tânia M B L ^a  

^a HOSPITAL GERAL DE FORTALEZA   (Brazil)

^b FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Acromegaly; Cabergoline; McCune Albright syndrome; Pituitary adenoma; Somatostatin

Indexed keywords

EID: 66149140187     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302009000100015     Document Type: Article

References (26)

1. McCune DJ. Osteitis fibrosa cystica: the case of a nine-year-old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child. 1936;52:743-4.
2. Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas, of pigmentation, and endocrine dysfunction, with precocious puberty in females: report of 5 cases. N Engl J Med. 1937;216:727-46.
3. Akintoye SO, Chebli C, Booher S, Feuillan P, Kushner H, Leroith D, et al. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome. J Clin Endocrinol Metab. 2002;87:5104-12.
4. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med. 1991;325(24):1688-95.
5. Obuobie K, Mullik V, Jones C, John R, Rees AE, Davies JS, et al. McCune-Albright syndrome: growth hormone dynamics in pregnancy. J Clin Endocrinol Metab. 2001;86(6):2456-8.
6. Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J Rare Dis. 2008;19:3-12.
7. Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001;22:675-705.
8. Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, et al. Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr. 1993;123:509-18.
9. Bhansali A, Sharma BS, Sreenivasulu P, Singh P, Vashisth RK, Dash RJ. Acromegaly with fibrous dysplasia: McCune-Albright Syndrome - clinical studies in 3 cases and brief review of literature. Endocr J. 2003;50(6):793-9.
10. Mock D, Rosen IB. Osteosarcoma in irradiated fibrous dysplasia. J Oral Pathol. 1986;15:1-4.
11. Mortensen A, Bojsen-Moller M, Rasmussen P. Fibrous dysplasia of the skull with acromegaly and sarcomatous transformation. Two cases with a review of the literature. J Neurooncol. 1989;7:25-9.
12. Ruggieri P, Sim FH, Bond JR, Unni KK. Malignancies in fibrous dysplasia. Cancer. 1994;73:1411-4.
13. Hansen MR, Moffat JC. Osteosarcoma of the skull base after radiation therapy in a patient with McCune-Albright syndrome: case report. Skull Base. 2003;13:79-83.
14. Chanson P, Dib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol. 1994;131:229-34.
15. Premawardhana LD, Vora JP, Mills R, Scanlon MF. Acromegaly and its treatment in the McCune-Albright syndrome. Clin Endocrinol (Oxf). 1992;36(6):605-8.
16. Schoof E, Dörr HG, Kiess W, Lüdecke DK, Freitag E, Zindel V, et al. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism-effect of octreotide therapy. Horm Res. 2004;61(4):184-9.
17. Feuillan PP, Jones J, Ross JL. Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog. J Clin Endocrinol Metab. 1995;80(4):1357-60.
18. Tajima T, Tsubaki J, Ishizu K, Jo W, Ishi N, Fujieda K. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. Endocr J. 2008;55(3):595-9.
19. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007;67(2):282-9.
20. Selvarajah D, Webster J, Ross R, Newell-Price J, Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152:569-74.
21. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2005;91:85-92.
22. Petrossians P, Borges-Martins L, Espinoza C, Daly A, Betea D, Valdes-Socin H, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol. 2005;152:61-6.
23. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders MD, Janssen JA, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365:1644-6.
24. Jorgensen J, Feldt-Rasmussen U, Frystyk J, Chen J, Kristensen L, Hagen C, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90:5627-31.
25. Galland F, Kamenicky P, Affres H, Reznik Y, Pontvert D, Le Bouc Y, et al. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analogresistant patients. J Clin Endocrinol Metab. 2006;91(12):4957-61.
26. Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, et al. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J. 2006;53(1):125-32.